We have granted anti-dilution protections as follows:
- On October 10, 2023, the Company entered into a Securities Purchase Agreement (as amended, the "CA Purchase Agreement") with Presto CA LLC ("CA"), a related party, pursuant to which the Company sold 1,500,000 shares of common stock, at a purchase price of $2.00 per share, for an aggregate purchase price of $3.0 million (the "Private Placement"). The Private Placement closed on October 16, 2023. The CA Purchase Agreement includes anti-dilution provisions relating to future issuances or deemed issuances of the Company's common stock from October 16, 2023 to April 1, 2024 at a price per share below $2.00, which would require the Company to issue additional shares of common stock to CA, upon the terms and subject to the conditions contained in the CA Purchase Agreement. On March 21, 2024, the Company entered into a second amendment (the "Second Amendment") to the CA Purchase Agreement, pursuant to which (i) the period subject to anti-dilution protections was extended through September 30, 2024 and (ii) the current trigger price for anti-dilution protection was updated to $0.25 per share following other recent offerings by the Company.
- On October 10, 2023, the Company entered into a Third Amendment (the "Third Amendment") to the Credit Agreement, pursuant to which the Lenders agreed to, among other things, exchange an aggregate of $6,000,000 of accrued and previously capitalized interest for warrants to purchase 3,000,000 shares of common stock at a purchase price of $0.01 per share (as amended, the "Third Amendment Conversion Warrants"). The Third Amendment Conversion Warrants are subject to anti-dilution provisions relating to future issuances or deemed issuances of the Company's common stock from October 16, 2023 to April 1, 2024 at a price per share below $2.00, upon the terms and subject to the conditions contained in the Third Amendment Conversion Warrants. On March 21, 2024, the Company amended and restated the Third Amendment Conversion Warrants, pursuant to which (i) the period subject to anti-dilution protections was extended through September 30, 2024 and (ii) the current trigger price for anti-dilution protection was updated to $0.25 per share following other recent offerings by the Company.
- On November 17, 2023, the Company entered into Purchase Agreements (the "November 2023 Purchase Agreements") for the issuance of 7,750,000 shares of common stock for $7.0 million (the "November Offering") including 750,000 shares issued to a related party. The November 2023 Purchase Agreements include anti-dilution provisions relating to future issuances or deemed issuances of the Company's common stock from November 21, 2023 to April 1, 2024 at a price per share below $1.00, which required the Company to issue additional shares of common stock to the purchasers when this provision was triggered upon issuance of the January 2024 Convertible Notes, upon the terms and subject to the conditions contained in the November 2023 Purchase Agreements.
- On January 31, 2024, the Company entered into a Fifth Amendment (the "Fifth Amendment") to the Credit Agreement, pursuant to which the Company issued to the Agent warrants to purchase 5,323,298 shares of common stock at a purchase price of $0.01 per share (as amended, the "Fifth Amendment Warrants") in exchange for a reduction in interest rate on the outstanding loan under the Credit Agreement from 12% to 8%. The Fifth Amendment Warrants are subject to anti-dilution provisions relating to future issuances or deemed issuances of the Company's common stock from January 31, 2024 to April 1, 2024 at a price per share below $0.40, upon the terms and subject to the conditions contained in the Fifth Amendment Conversion Warrants. On March 21, 2024, the Company amended and restated the Fifth Amendment Warrants, pursuant to which (i) the period subject to anti-dilution protections was extended through September 30, 2024 and (ii) the current trigger price for anti-dilution protection was updated to $0.25 per share following other recent offerings by the Company.
The November Offering triggered the anti-dilution provisions in the CA Purchase Agreement and the Third Amendment Conversion Warrants. The Company agreed with each of CA and the Lenders that the "New Issuance Price" (as defined in the CA Purchase Agreement and Third Amendment Conversion Warrants, respectively) would be $1.00. As a result, we were required to issue an additional 1,500,000 shares to CA and increase the amount of common stock issuable upon the exercise of the Third Amendment Conversion Warrants from 3,000,000 shares to 6,000,000 shares.
The January 2024 Convertible Notes triggered the anti-dilution provisions in the CA Purchase Agreement, the Third Amendment Conversion Warrants and the November Purchase Agreements. In connection with the January 2024 Convertible Notes, the Lenders, CA and the holders of 3,000,000 out of the 4,000,000 shares issued in the November 2023 Offering that were not being forfeited agreed that the "New Issuance Price" for the purpose of anti-dilution protection regarding the January 2024 Convertible Notes would be $0.40 and not $0.25. For the one investor holding 1,000,000 shares, the "New Issuance Price" was $0.25. As a result, we were required to (i) issue an additional 4,500,000 shares to CA, (ii) increase the amount of common stock issuable upon the exercise of the Third Amendment Conversion Warrants from 6,000,000 shares to 15,000,000 shares and (iii) issue an additional 7,500,000 shares to the November 2023 Purchasers. Additional shares issued includes the one investor holding 1,000,000 shares who received 3,000,000 additional shares and excludes the Lead Investor holding 3,000,000 shares that were forfeited and exchanged for $3.0 million principal amount of subordinated notes.
The February Offering triggered anti-dilution provisions in the CA Purchase Agreement, Third Amendment Conversion Warrants, the Fifth Amendment Warrants and the November Purchase Agreements (with respect to the November 2023 Purchasers that had previously agreed to the "New Issuance Price" of $0.40). The Company agreed with each of CA and the Lenders that the "New Issuance Price" (as defined in the CA Purchase Agreement, the Third Amendment Conversion Warrants and the Fifth Amendment Warrants, respectively) would be $0.25. As a result, we were required to (i) issue an additional 4,500,000 shares to CA, (ii) increase the amount of common stock issuable upon the exercise of the Third Amendment Conversion Warrants from 15,000,000 shares to 24,000,000 shares, (iii) increase the amount of common stock issuable upon the exercise of the Fifth Amendment Warrants from 5,323,298 shares to 8,517,278 shares, and (iv) issue an additional 4,500,000 shares to the November 2023 Purchasers that had previously agreed to the "New Issuance Price" of $0.40.
If the foregoing anti-dilution provisions are triggered again in the future, (for example, refer to Note 15 in Part I, Item 1, of this Quarterly Report on Form 10-Q, Triggering and Partial Waiver of Anti-dilution Protection Associated with Previously Issued Securities, for details of the anti-dilution adjustment provision triggered upon the issuance of the January 2024 Convertible Notes and the February Offering) the issuance of additional shares thereunder will further dilute the percentage ownership interest of all stockholders, will dilute the book value per share of the Company's common stock and will increase the number of the Company's outstanding shares, which could depress the market price of the Company's common stock.